For most of the 2000s and early 2010s, Germany was one of the premier destinations for medical tourism, drawing self-paying and state-sponsored patients from Russia, the former Soviet republics and the Gulf. That business has been shrinking since the middle of the last decade, and the common explanation, that cheaper rivals such as Turkey took the patients, covers only part of it. The larger part is internal. A series of billing scandals broke the trust of the state payers who funded the trade, two changes in German law closed the commercial channel it ran through, the hospital sector fell into a staffing and financing crisis that made foreign patients a burden rather than extra income, and a change in how senior doctors are paid removed the personal incentive that once drove clinicians to pursue the work. This article sets out those factors in turn.
This report concentrates on the internal, legal and systemic causes. For the wider view of the fall, including the market data and the demand-side story, see our companion overview of the decline of medical tourism in Germany.
Text description of the diagram
Five forces, three mechanisms, one outcome.
Demand side. 01 Source-market shocks. Russia: EU sanctions, weak rouble, 2022 war. Gulf: budget cuts, VAT, embassy reform.
Systemic, Germany. 02 Billing scandals. Libyan war-wounded losses and the Kuwaiti embassy-patient affair erode payer trust. 03 Legal change closes the channel. §299a/b StGB (2016) can criminalise paid referrals. §138 BGB (LG Kiel 2011, LG Stuttgart 2024) makes brokerage contracts void.
Supply side. 04 Hospital staffing and funding crisis. Nurse and bed shortages and deficits turn foreign patients into a burden, not income. 05 Doctors' pay incentive removed. Liquidationsrecht gives way to Beteiligungsvergütung: the hospital keeps the fee.
Mechanisms. Forces 01 and 02 drive demand falls among premium non-EU patients. Force 03 closes the acquisition channel. Forces 04 and 05 collapse provider willingness. Competition, from Turkey and from Gulf states building their own capacity, is an accelerant rather than a root cause.
Outcome. The premium inbound business collapses. Low-value EU cross-border day-traffic masks the fall in the profitable core.
The scale of Germany’s medical tourism decline
Germany’s inbound patient numbers peaked in the middle of the last decade and have trended down since. The most-cited data comes from the Hochschule Bonn-Rhein-Sieg, whose researchers have tracked the German market for years. Their figures put the country at around 255,000 foreign patients in 2015, then about 253,000 in 2016 and roughly 247,500 in 2017, with revenue holding near 1.2 billion euros. On the surface that looks like a modest, gradual decline. Beneath it the picture is sharper.
The headline count masked what was happening underneath. By 2018, close to two-thirds of all foreign patients came from within the EU, most of them from Poland, and much of that is low-value cross-border and day-case traffic. The consulting firm MESC frames the same split from the operator’s side, noting that of up to 250,000 foreign patients a year, only around 40 to 45 per cent are true medical tourists, most from neighbouring Europe, followed by the Gulf and the former Soviet states. The premium segment, the non-EU inpatient business that hospitals built dedicated international departments to capture, is the part that collapsed. The aggregate number fell gently; the profitable core fell hard. That is why the sector is much diminished even where the raw statistics look only modestly lower.
The source markets collapsed
The two markets that made German medical tourism lucrative, Russia and the Gulf, both contracted for reasons largely outside German control. Russia was the single biggest source country. From 2014, the falling rouble, the low oil price and EU sanctions made treatment in Germany far more expensive, and the Hochschule Bonn-Rhein-Sieg reported that Russians increasingly travelled only for urgent cases. The 2022 invasion of Ukraine, with the banking cut-off, airspace closures and political rupture that followed, ended most of what remained.
The Gulf decline was steeper in places and more instructive, because it was not only about money. Budget deficits, the introduction of VAT in Saudi Arabia and the United Arab Emirates, and general spending cuts reduced the funds Gulf governments set aside for foreign treatment. But the German trade press has consistently pointed to a change in behaviour as much as budget: the once-generous payers began scrutinising German invoices closely and sending fewer patients where they suspected overcharging. Kuwait, once a flagship market, fell by 62 per cent in a single year, with Saudi Arabia and Oman also down sharply. That shift toward suspicion did not come from nowhere.
Billing scandals broke payer trust
The trust the trade depended on was broken by a series of billing scandals in the mid-2010s, and German commentators have named these directly as a cause of the Gulf pull-back. The most documented is the case of a Stuttgart teaching hospital, whose international unit treated around 370 Libyan war-wounded and ran up a roughly nine-million-euro deficit, amid cash carried in suitcases and disordered bookkeeping. Analysts at the Hochschule Bonn-Rhein-Sieg listed that affair, alongside inflated billing of Libyan patients more generally and the disappearance of large sums in the treatment of Kuwaiti embassy patients, in a picture that Kuwaiti media called one of the largest frauds they had seen, with a state commission examining hospital and agency contracts.
The trade analysis was blunt about the effect. Reporting in the German sector press tied the collapse in Arab-region patient numbers from late 2016 to three things together: reduced Gulf funding, structural changes in the embassies and consulates, and the scandal around the Stuttgart hospital’s international department. When a business rests on a handful of foreign ministries and those ministries conclude they are being overbilled, they redirect the flow rather than renegotiate.
The law closed the intermediary channel
Two developments in German law removed the commercial machinery that the inbound trade ran on, and this is the internal factor most often overlooked outside Germany. The business depended on agents and facilitators who were paid a commission to steer patients to particular clinics. Since June 2016, that model has been legally hazardous, because Sections 299a and 299b of the Criminal Code extended anti-corruption law across the healthcare sector, so that demanding or granting a benefit for referring patients can, in the right circumstances, be treated as a criminal offence. The provisions are not a blanket ban on working with intermediaries, but they raised the level of scrutiny sharply, and with it the legal requirements for structuring these partnerships. MESC, which advises on exactly this problem, has set out how these provisions apply to patient brokerage in its explainer on the Sections 299a and 299b question in medical tourism.
The civil law then closed the same door from the other side, and it did so long before the recent cases. The foundational ruling came from the Regional Court of Kiel in 2011, which held that a commission contract for referring patients to a hospital is immoral and void under Section 138 of the Civil Code. That case sits squarely on theme: a doctor with contacts in the Gulf had agreed with a university hospital’s international department to channel private patients from Oman and the United Arab Emirates in return for a commission of 15 to 22.5 per cent of the hospital’s income, and the court dismissed his fee claim and extended the doctors’ referral ban to the hospital itself. The Regional Court of Stuttgart confirmed and widened that line in November 2024, ruling that such commissions are void even in federal states whose hospital laws contain no explicit prohibition, that the so-called hospital privilege does not save them, and that a brokerage arrangement bundled with interpreting or visa help is void in its entirety, denying a claim of 119,000 euros. MESC, which advises on exactly this problem, has argued that the compliant contractual constellations which remain tend to be uneconomic enough that clinic and agency simply drop the cooperation. For any provider still weighing the business, the message is that the standard way of acquiring international patients is now legally unsafe.
Payment risk became a deterrent
Even where a foreign patient did come, collecting the fee became a structural risk that pushed finance directors away from the trade. Once a self-paying patient has flown home, recovery is difficult and slow, and if the intermediary refuses to pay, the hospital is left litigating in a foreign jurisdiction. German case law shows how this plays out: in one 2023 matter, a hospital’s claim of around 130,000 euros against an agency failed because it could not prove the agency had agreed to cover the costs. Cases like these taught hospitals to treat unsecured foreign-patient revenue as a bad-debt risk rather than easy income, and many concluded the margin did not justify the exposure.
The domestic hospital crisis
For years, international patients were presented internally as extra revenue on top of the case-based hospital budget, and that logic holds only when a hospital has spare beds and spare staff. Germany now has neither. The nursing shortage became acute enough to drive strikes for binding staffing ratios at major Berlin hospitals, and once beds and nurses are the constraint, a foreign self-payer stops being extra income and becomes a bed a domestic patient needs, with the added optics of queue-jumping.
During the pandemic this became explicit and public. At Hamburg’s university hospital, the drop in foreign patients was reported as a board decision not to fill beds with them rather than a lack of demand, while at a large Munich university hospital the international business largely came to a standstill. The exits followed. Düsseldorf University Hospital stopped targeting international patients, saying the revenue was no longer important, and Berlin’s Vivantes closed its central international-medicine unit, explaining that Gulf states were setting different priorities and signing contracts with other countries, so remaining non-EU patients would be handled directly by specialist departments. When institutions this large decide the business is not worth the beds, the market has already turned.
The shift in doctors’ pay incentives
The final factor concerns how senior hospital doctors are paid, and it removed their personal reason to pursue foreign patients. Under the traditional model, a chief physician holding a personal billing right, the Liquidationsrecht, could invoice elective physician services directly to private patients under the German medical fee schedule and keep the income, paying the hospital only a usage fee. Foreign self-payers and embassy patients fall squarely into this, billed as private patients, so the senior doctor who attracted a Gulf or Russian patient was in large part billing for their own account. The German medical press has described private liquidation as making up a large share of chief-physician pay, and the trade literature of the era was explicit that treating foreign private patients could be very lucrative for the chief physician, especially where the hospital itself was under financial pressure.
That personal upside has thinned out. New chief-physician contracts increasingly grant no personal billing right at all, only a share of the proceeds, a Beteiligungsvergütung, while the hospital holds the billing right and books the revenue itself. This is not one reform statute but a structural, contractual migration, pushed by the German Hospital Federation and enabled by the fact that a chief physician has no enforceable right to be granted the billing privilege in the first place. The consequence for international patients is direct. The clinician most able to attract them, the specialist the patient travelled for, no longer captures the upside; the hospital does. And the hospital, as above, increasingly did not want the business. The two incentives that once pointed the same way, the doctor’s private motive and the institution’s revenue motive, weakened at roughly the same time.
Competition as accelerant
External competition then completed what the internal failures had started, though it is better understood as the accelerant than the root cause. For Arabic-speaking markets in particular, Turkey grew attractive because its surgeons were often German- or US-trained and share the patients’ faith, while the Gulf states built their own tertiary capacity and, as Vivantes noted, signed bilateral treatment agreements elsewhere. The competition bit hard because Germany had already hollowed out its own trust, its legal channel, its payment security and its institutional appetite. With those foundations intact a market can absorb new competitors. Germany’s could not, because they had already given way.
What it means for the sector
The German case shows how a high-value inbound market can be fragile beneath strong headline numbers. It depended on opaque, intermediary-driven flows from a small set of volatile state payers, and it had little professionalised base to fall back on when conditions turned. Only around 10 to 12 per cent of German hospitals ever ran the business seriously, and the Hochschule Bonn-Rhein-Sieg’s standing point was that international work is not a self-runner, demanding trained staff, real relationships in the source countries and constant oversight. When the scandals broke payer trust, the anti-corruption law and the civil-law rulings closed the commission channel, the domestic system ran short of beds and staff, and the pay shift removed the clinician’s private incentive, the lucrative core of the trade had nothing structural to stand on.
The cross-border EU day-traffic that remains is real, but it was never the business anyone meant when they spoke of medical tourism to Germany. For destinations and providers elsewhere, the lesson is that trust, a legally sound acquisition model, secured payment and genuine institutional commitment are not optional extras. They are foundations, and the German experience shows what happens when they give way together.
Frequently asked questions
Why did medical tourism to Germany decline?
It declined for several reasons at once, most of them internal. The high-value source markets in Russia and the Gulf contracted, a run of billing scandals broke the trust of the state payers who funded the trade, a 2016 anti-corruption law and a 2024 Stuttgart court ruling closed the commission-based channel that agents relied on, the hospital sector ran short of beds and staff, and a shift in how senior doctors are paid removed their personal incentive to pursue foreign patients. Cheaper competition abroad accelerated the fall rather than causing it.
When did medical tourism to Germany peak?
It peaked around 2015, at roughly 255,000 foreign patients and about 1.2 billion euros in revenue, according to data from the Hochschule Bonn-Rhein-Sieg. The headline count then fell only gently, but the profitable non-EU segment collapsed underneath it.
Is Germany still a medical tourism destination?
Yes, but the lucrative part of the business has shrunk. By 2018 close to two-thirds of foreign patients came from within the EU, most of them from Poland, and much of that is low-value cross-border and day-case traffic rather than the premium inpatient work the sector was built on.
Which German laws affected medical tourism?
Two are central. Sections 299a and 299b of the Criminal Code, in force since June 2016, mean that granting or demanding a benefit for referring patients can amount to a criminal offence in certain circumstances, and they raised both the scrutiny applied to these arrangements and the legal requirements for structuring them. On the civil side, the Regional Court of Kiel held in 2011 that commission-based patient brokerage to a hospital is void under Section 138 of the Civil Code, and the Regional Court of Stuttgart confirmed and widened this in November 2024, ruling that it applies even where a state’s hospital law contains no explicit ban.
